{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:19:25Z","timestamp":1782209965381,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00595-019-01924-4","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T14:02:29Z","timestamp":1574690549000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy"],"prefix":"10.1007","volume":"50","author":[{"given":"Shimpei","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Ariake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Mizuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuhiko","family":"Motoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Naitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"1","key":"1924_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"1924_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267\u201377. https:\/\/doi.org\/10.1001\/jama.297.3.267.","journal-title":"JAMA"},{"issue":"10","key":"1924_CR3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073\u201381. https:\/\/doi.org\/10.1001\/jama.2010.1275.","journal-title":"JAMA"},{"issue":"10041","key":"1924_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9.","journal-title":"Lancet"},{"issue":"10073","key":"1924_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(16)32409-6.","journal-title":"Lancet"},{"issue":"4","key":"1924_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/00000658-194310000-00008","volume":"118","author":"EW Rockey","year":"1943","unstructured":"Rockey EW. Total pancreatectomy for carcinoma: case report. Ann Surg. 1943;118(4):603\u201311.","journal-title":"Ann Surg."},{"issue":"5","key":"1924_CR7","first-page":"418","volume":"40","author":"MG Sarr","year":"1993","unstructured":"Sarr MG, Behrns KE, van Heerden JA. Total pancreatectomy An objective analysis of its use in pancreatic cancer. Hepatogastroenterology. 1993;40(5):418\u201321.","journal-title":"Hepatogastroenterology."},{"issue":"3","key":"1924_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s002689900046","volume":"20","author":"I Ihse","year":"1996","unstructured":"Ihse I, Anderson H, Andren S. Total pancreatectomy for cancer of the pancreas: Is it appropriate? World J Surg. 1996;20(3):288\u201393 (discussion 94.).","journal-title":"World J Surg."},{"issue":"9","key":"1924_CR9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/hpb.12203","volume":"16","author":"KJ Roberts","year":"2014","unstructured":"Roberts KJ, Blanco G, Webber J, Marudanayagam R, Sutcliffe RP, Muiesan P, et al. How severe is diabetes after total pancreatectomy? A case-matched analysis. HPB (Oxford). 2014;16(9):814\u201321. https:\/\/doi.org\/10.1111\/hpb.12203.","journal-title":"A case-matched analysis. HPB (Oxford)"},{"issue":"5","key":"1924_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00268-015-2948-1","volume":"39","author":"Y Watanabe","year":"2015","unstructured":"Watanabe Y, Ohtsuka T, Matsunaga T, Kimura H, Tamura K, Ideno N, et al. Long-term outcomes after total pancreatectomy: special reference to survivors' living conditions and quality of life. World J Surg. 2015;39(5):1231\u20139. https:\/\/doi.org\/10.1007\/s00268-015-2948-1.","journal-title":"World J Surg."},{"issue":"3","key":"1924_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/MPA.0000000000000462","volume":"45","author":"T Hata","year":"2016","unstructured":"Hata T, Ishida M, Motoi F, Sakata N, Yoshimatsu G, Naitoh T, et al. Clinical characteristics and risk factors for the development of postoperative hepatic steatosis after total pancreatectomy. Pancreas. 2016;45(3):362\u20139. https:\/\/doi.org\/10.1097\/MPA.0000000000000462.","journal-title":"Pancreas"},{"issue":"3","key":"1924_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/SLA.0000000000000791","volume":"261","author":"W Hartwig","year":"2015","unstructured":"Hartwig W, Gluth A, Hinz U, Bergmann F, Spronk PE, Hackert T, et al. Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation. Ann Surg. 2015;261(3):537\u201346. https:\/\/doi.org\/10.1097\/SLA.0000000000000791.","journal-title":"Ann Surg."},{"issue":"1","key":"1924_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.hpb.2015.07.009","volume":"18","author":"WC Johnston","year":"2016","unstructured":"Johnston WC, Hoen HM, Cassera MA, Newell PH, Hammill CW, Hansen PD, et al. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the national cancer data base. HPB (Oxford). 2016;18(1):21\u20138. https:\/\/doi.org\/10.1016\/j.hpb.2015.07.009.","journal-title":"HPB (Oxford)."},{"issue":"7","key":"1924_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/MPA.0000000000000579","volume":"45","author":"S Satoi","year":"2016","unstructured":"Satoi S, Murakami Y, Motoi F, Sho M, Matsumoto I, Uemura K, et al. Reappraisal of total pancreatectomy in 45 patients with pancreatic ductal adenocarcinoma in the modern era using matched-pairs analysis: multicenter study group of pancreatobiliary surgery in Japan. Pancreas. 2016;45(7):1003\u20139. https:\/\/doi.org\/10.1097\/MPA.0000000000000579.","journal-title":"Pancreas"},{"key":"1924_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijsu.2017.10.065","volume":"48","author":"J Xiong","year":"2017","unstructured":"Xiong J, Wei A, Ke N, He D, Chian SK, Wei Y, et al. A case-matched comparison study of total pancreatectomy versus pancreaticoduodenectomy for patients with pancreatic ductal adenocarcinoma. Int J Surg. 2017;48:134\u201341. https:\/\/doi.org\/10.1016\/j.ijsu.2017.10.065.","journal-title":"Int J Surg."},{"issue":"2","key":"1924_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/SLA.0b013e3181ae9f93","volume":"250","author":"S Reddy","year":"2009","unstructured":"Reddy S, Wolfgang CL, Cameron JL, Eckhauser F, Choti MA, Schulick RD, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg. 2009;250(2):282\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e3181ae9f93.","journal-title":"Ann Surg."},{"key":"1924_CR17","unstructured":"Japan Pancreas Society. Classification of Pancreatic Carcinoma. 4th English ed. Tokyo: Kanehara & Co., Ltd; 2017. https:\/\/www.suizou.org\/pdf\/Classification_of_Pancreatic_Carcinoma_4th_Engl_ed.pdf Accessed April 10 2019."},{"issue":"2","key":"1924_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b13ca2.","journal-title":"Ann Surg."},{"issue":"4","key":"1924_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00000658-197010000-00006","volume":"172","author":"WH ReMine","year":"1970","unstructured":"ReMine WH, Priestley JT, Judd ES, King JN. Total pancreatectomy. Ann Surg. 1970;172(4):595\u2013604.","journal-title":"Ann Surg."},{"issue":"6","key":"1924_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/00000658-197712000-00002","volume":"186","author":"I Ihse","year":"1977","unstructured":"Ihse I, Lilja P, Arnesjo B, Bengmark S. Total pancreatectomy for cancer. An appraisal of 65 cases. Ann Surg. 1977;186(6):675\u201380.","journal-title":"Ann Surg."},{"issue":"4","key":"1924_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/00000658-198904000-00003","volume":"209","author":"JR Brooks","year":"1989","unstructured":"Brooks JR, Brooks DC, Levine JD. Total pancreatectomy for ductal cell carcinoma of the pancreas. An update. Ann Surg. 1989;209(4):405\u201310.","journal-title":"Ann Surg."},{"issue":"2","key":"1924_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jso.21189","volume":"99","author":"H Nathan","year":"2009","unstructured":"Nathan H, Wolfgang CL, Edil BH, Choti MA, Herman JM, Schulick RD, et al. Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective. J Surg Oncol. 2009;99(2):87\u201392. https:\/\/doi.org\/10.1002\/jso.21189.","journal-title":"J Surg Oncol."},{"issue":"1","key":"1924_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/archsurg.136.1.44","volume":"136","author":"HM Karpoff","year":"2001","unstructured":"Karpoff HM, Klimstra DS, Brennan MF, Conlon KC. Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg. 2001;136(1):44\u20137 (discussion 8.).","journal-title":"Arch Surg."},{"issue":"4","key":"1924_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1072-7515(98)00327-5","volume":"188","author":"NB Merchant","year":"1999","unstructured":"Merchant NB, Conlon KC, Saigo P, Dougherty E, Brennan MF. Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg. 1999;188(4):421\u20136.","journal-title":"J Am Coll Surg."},{"issue":"10","key":"1924_CR25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.gassur.2006.07.013","volume":"10","author":"CR Ferrone","year":"2006","unstructured":"Ferrone CR, Haas B, Tang L, Coit DG, Fong Y, Brennan MF, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg. 2006;10(10):1347\u201353. https:\/\/doi.org\/10.1016\/j.gassur.2006.07.013.","journal-title":"J Gastrointest Surg."},{"issue":"13","key":"1924_CR26","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/bjs.9307","volume":"100","author":"S Yamada","year":"2013","unstructured":"Yamada S, Fujii T, Kanda M, Sugimoto H, Nomoto S, Takeda S, et al. Value of peritoneal cytology in potentially resectable pancreatic cancer. Br J Surg. 2013;100(13):1791\u20136. https:\/\/doi.org\/10.1002\/bjs.9307.","journal-title":"Br J Surg."},{"issue":"1","key":"1924_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11605-014-2637-7","volume":"19","author":"S Satoi","year":"2015","unstructured":"Satoi S, Murakami Y, Motoi F, Uemura K, Kawai M, Kurata M, et al. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. J Gastrointest Surg. 2015;19(1):6\u201314. https:\/\/doi.org\/10.1007\/s11605-014-2637-7(discussion).","journal-title":"J Gastrointest Surg."},{"issue":"4","key":"1924_CR28","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.surg.2016.10.035","volume":"161","author":"T Abe","year":"2017","unstructured":"Abe T, Ohuchida K, Endo S, Ookubo F, Mori Y, Nakata K, et al. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Surgery. 2017;161(4):951\u20138. https:\/\/doi.org\/10.1016\/j.surg.2016.10.035.","journal-title":"Surgery."},{"issue":"5","key":"1924_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2168.2002.02061.x","volume":"89","author":"S Yachida","year":"2002","unstructured":"Yachida S, Fukushima N, Sakamoto M, Matsuno Y, Kosuge T, Hirohashi S. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg. 2002;89(5):573\u20138. https:\/\/doi.org\/10.1046\/j.1365-2168.2002.02061.x.","journal-title":"Br J Surg."},{"issue":"3","key":"1924_CR30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/000313480407000305","volume":"70","author":"IM Meszoely","year":"2004","unstructured":"Meszoely IM, Lee JS, Watson JC, Meyers M, Wang H, Hoffman JP. Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas. Am Surg. 2004;70(3):208\u201313 (discussion 13\u20134).","journal-title":"Am Surg."},{"issue":"9","key":"1924_CR31","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00268-012-1622-0","volume":"36","author":"R Yoshioka","year":"2012","unstructured":"Yoshioka R, Saiura A, Koga R, Arita J, Takemura N, Ono Y, et al. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. World J Surg. 2012;36(9):2187\u201391. https:\/\/doi.org\/10.1007\/s00268-012-1622-0.","journal-title":"World J Surg."},{"issue":"1","key":"1924_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.amjsurg.2016.04.008","volume":"213","author":"SY Oh","year":"2017","unstructured":"Oh SY, Edwards A, Mandelson MT, Hahn H, Alseidi A, Biehl T, et al. Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. Am J Surg. 2017;213(1):94\u20139. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.04.008.","journal-title":"Am J Surg."},{"issue":"19","key":"1924_CR33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med."},{"issue":"18","key":"1924_CR34","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med."},{"issue":"7","key":"1924_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/bjc.2015.328","volume":"113","author":"A Portal","year":"2015","unstructured":"Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113(7):989\u201395. https:\/\/doi.org\/10.1038\/bjc.2015.328.","journal-title":"Br J Cancer."},{"issue":"1","key":"1924_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1245\/s10434-014-3898-9","volume":"22","author":"L Marthey","year":"2015","unstructured":"Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22(1):295\u2013301. https:\/\/doi.org\/10.1245\/s10434-014-3898-9.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"1924_CR37","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","volume":"22","author":"S Moningi","year":"2015","unstructured":"Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, et al. The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol. 2015;22(7):2352\u20138. https:\/\/doi.org\/10.1245\/s10434-014-4274-5.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"1924_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.pan.2019.01.001","volume":"19","author":"I Matsumoto","year":"2019","unstructured":"Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N, et al. FOLFIRINOX for locally advanced pancreatic cancer: results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. Pancreatology. 2019;19(2):296\u2013301. https:\/\/doi.org\/10.1016\/j.pan.2019.01.001.","journal-title":"Pancreatology"},{"issue":"10","key":"1924_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/RLU.0b013e31829f8c90","volume":"38","author":"SY Moon","year":"2013","unstructured":"Moon SY, Joo KR, So YR, Lim JU, Cha JM, Shin HP, et al. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET\/CT in patients with locally advanced or metastatic pancreatic cancer. Clin Nucl Med. 2013;38(10):778\u201383. https:\/\/doi.org\/10.1097\/RLU.0b013e31829f8c90.","journal-title":"Clin Nucl Med."},{"issue":"8","key":"1924_CR40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.gassur.2003.09.002","volume":"7","author":"C Sperti","year":"2003","unstructured":"Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003;7(8):953\u20139 (discussion 9\u201360).","journal-title":"J Gastrointest Surg."},{"key":"1924_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-017-3627-3","author":"K Ariake","year":"2017","unstructured":"Ariake K, Motoi F, Shimomura H, Mizuma M, Maeda S, Terao C, et al. 18-fluorodeoxyglucose positron emission tomography predicts recurrence in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2017. https:\/\/doi.org\/10.1007\/s11605-017-3627-3.","journal-title":"J Gastrointest Surg."}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-019-01924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00595-019-01924-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-019-01924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T09:03:22Z","timestamp":1695459802000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00595-019-01924-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1007\/s00595-019-01924-4","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"5 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}